دانلود کتاب Amine Oxidases and Their Impact on Neurobiology: Proceedings of the 4th International Amine Oxidases Workshop, Wurzburg, Federal Republic of Germany, July 7–10, 1990

فهرست مطالب :

Front Matter....Pages I-XII
Front Matter....Pages 1-1
The interaction of transport mechanisms and intracellular enzymes in metabolizing systems....Pages 3-18
In-vivo quantitative imaging of catecholaminergic nerve terminals in brain and peripheral organs using positron emission tomography (PET)....Pages 19-27
The mechanism of action of antidepressants revised....Pages 29-37
Front Matter....Pages 39-39
The expression of human MAO-A and B genes....Pages 41-47
Molecular neuroanatomy of MAO-A and MAO-B....Pages 49-53
Turnover of monoamine oxidase B (MAO-B) in pig brain by positron emission tomography using 11 C-L-deprenyl....Pages 55-59
Visualisation of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer’s type by means of large cryosection autoradiography: a pilot study....Pages 61-65
Immuno-fluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of monoamine oxidase A and monoamine oxidase B: a pilot study....Pages 67-77
Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study....Pages 79-84
In vivo studies on the effect of monoamine oxidase inhibitors on dopamine and serotonin metabolism in rat brain areas....Pages 85-88
Some pharmacological implications of MAO-mediated deamination of branched aliphatic amines: 2-Propyl-1-aminopentane and N-(2-propylpentyl)glycinamide as valproic acid precursors....Pages 89-92
[ 3 H] Harman labels selectively and with high affinity the active site of monoamine oxidase (EC 1.4.3.4) subtype A (MAO-A) in rat, marmoset, and pig....Pages 93-102
Inhibition of MAO by substituted tryptamine analogues....Pages 103-105
Ring-substituted analogues of tranylcypromine as monoamine oxidase inhibitors....Pages 107-112
Recent studies on the MAO inhibitor phenelzine and its possible metabolites....Pages 113-118
Stylbasole analogues of MPTP as monoamine oxidase (MAO) substrates....Pages 119-122
MAO activity, metabolism and anticonvulsant activity of milacemide in rats and mice....Pages 123-129
Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in the rat....Pages 131-137
Effect of selegiline and desmethyl-selegiline on cortical electric activity in rats....Pages 139-144
An enzymatic method for detecting MAO-A and MAO-B inhibitors in plasma and its application in studies with reversible MAO-A selective inhibitors....Pages 145-148
Front Matter....Pages 39-39
Serotonin and 5-hydroxyindoleacetic acid in plasma. Potential use as peripheral measures of MAO-A activity....Pages 149-154
Role of monoamine oxidase A and B in the deamination of newly-formed dopamine in the rat kidney....Pages 155-159
Monoamine oxidase activity in blood platelets of migraine patients....Pages 161-164
Monoamine oxidase inhibition by moclobemide and 2-Aminoethyl carboxamide derivatives: mode of action and kinetic characteristics....Pages 165-170
Does moclobemide stimulate melatonin synthesis as the other selective MAO-A inhibitors do?....Pages 171-175
Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind Multicenter Study, Austria....Pages 177-184
Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide....Pages 185-188
Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder....Pages 189-195
Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography....Pages 197-201
A double-blind, placebo-controlled study of the tolerability and effects on platelet MAO-B activity of single oral doses of MDL 72.974A in normal volunteers....Pages 203-209
MAO-B inhibition in rabbit tissues and in human platelets by Ro 19-6327 shows similar time-course....Pages 211-214
Front Matter....Pages 215-215
Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP....Pages 217-227
Monoamine oxidase and oxidative stress at dopaminergic synapses....Pages 229-238
The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson’s disease....Pages 239-248
Oxidation of the indole nucleus of 5-hydroxytryptamine and formation of dimers in the presence of peroxidase and H 2 O 2 ....Pages 249-257
Reflection of changes in membrane constituents in various regions of Alzheimer brains to differential scanning thermograms....Pages 259-267
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism....Pages 269-275
Front Matter....Pages 277-277
Some aspects of the pharmacology of semicarbazide-sensitive amine oxidases....Pages 279-290
Intestinal diamine oxidases and enteral-induced histaminosis: studies on three prognostic variables in an epidemiological model....Pages 291-314
Methylamine oxidase from Arthrobacter P1 as a prototype of eukaryotic plasma amine oxidase and diamine oxidase....Pages 315-318
Front Matter....Pages 277-277
Chronic ethanol feeding and diamine oxidase activity in rat brain and liver....Pages 319-322
Amine oxidase activities in chemically-induced mammary cancer in the rat....Pages 323-326
Monoamine oxidase and semicarbazide-sensitive amine oxidase activities in bovine eye....Pages 327-330
Cultured preadipocytes produce a semicarbazide-sensitive amine oxidase (SSAO) activity....Pages 331-336
Semicarbazide-sensitive amine oxidase activity in rat aortic cultured smooth muscle cells....Pages 337-339
Amine oxidase activities in bovine lung....Pages 341-344
Mucosal mono- and polyamine oxidase activities in digestive tract are distributed complementary to diamine oxidase....Pages 345-349
Does FAD-dependent polyamine oxidase contribute to the metabolism of milacemide?....Pages 351-356
Behaviour and properties of catechol-O-methyltransferase from human placenta....Pages 359-368
Monoclonal antibodies recognizing both soluble and membrane bound catechol-O-methyltransferase....Pages 369-374
Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues....Pages 375-380
Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-DOPA in the rat....Pages 381-386
Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects....Pages 387-391
Front Matter....Pages 393-393
Oxidative deamination of noradrenaline in human blood vessels....Pages 395-404
Modification of alpha-2 presynaptic receptor activity and catecholamine release following chronic MAO inhibition....Pages 405-412
Biochemical characterization and purification of the neuronal sodium-dependent noradrenaline transporter....Pages 413-419
The importance of plasma 3,4-dihydroxyphenylglycol (DOPEG) in analyses of the sympathetic nervous system in vivo....Pages 421-429
The involvement of desipramine-sensitive processes in the extraction of various catecholamines from plasma in the anaesthetized rabbit....Pages 431-435
Human Caki-1 cells are the first model for extraneuronal transport of noradrenaline (uptake 2 ) which is based on a clonal cell line....Pages 437-440
The synaptic noradrenaline concentration in humans as estimated from simultaneous measurements of plasma noradrenaline and dihydroxyphenylglycol (DOPEG)....Pages 441-445
Front Matter....Pages 393-393
Inhibition of MAO activity, 3 H-imipramine binding, 3 H-paroxetine binding and 3 H-5-HT uptake by human cerebrospinal fluid....Pages 447-456
α 2 -Adrenoceptor responsivity in depression: effect of chronic treatment with moclobemide, a selective MAO-A-inhibitor, versus maprotiline....Pages 457-461
Supersensitivity to catecholamines after inhibition of extraneuronal uptake (uptake 2 ) or O-methylation....Pages 463-467
Front Matter....Pages 469-469
Urinary dopamine sulfate: regulations and significance in neurological disorders....Pages 471-479
Effect of adrenal-caudate transplantation on CSF levels of salsolinol sulfate in patients with Parkinson’s disease....Pages 481-484
Back Matter....Pages 485-491